Atara Biotherapeutics, Inc. (ATRA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 17, 2025

$6.57

P/E Ratio

N/A

Market Cap

$37.84M

Description

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Metrics

Overview

  • HQThousand Oaks, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerATRA
  • Price$6.57-16.09%

Trading Information

  • Market cap$37.84M
  • Float74.88%
  • Average Daily Volume (1m)340,815
  • Average Daily Volume (3m)173,933
  • EPS-$25.66

Company

  • Revenue$100.44M
  • Rev growth (1yr)1,779.79%
  • Net income-$21.91M
  • Gross margin81.08%
  • EBITDA margin-51.07%
  • EBITDA-$20.53M
  • EV$81.44M
  • EV/Revenue0.81
  • P/EN/A
  • P/S0.49
  • P/BN/A
Documents